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Abstract 
 
Introduction 
Haemodialysis (HD) patients are pro-thrombotic. Higher volume on-line post-dilutional 
haemodiafiltration (OL-HDF), with increasing haematocrit increases the risk of clotting in the 
extracorporeal circuit (ECC). We wished to determine whether OL-HDF increased platelet 
activation and ECC clotting. 
Methods 
Coagulation parameters, platelet, white cell and endothelial activation markers were 
measured at the start and end of dialysis sessions in 10 patients and also pre- and post-
dialyzer after 15 minutes using two different dialyzers designed for high volume OL-HDF; 
cellulose triacetate (TAGP) and polysulphone (PS) and polyvinylpyrrolidone (PVP). Patients 
were anticoagulated with a heparin bolus. 
Findings 
At the start of OL-HDF, D dimers, thrombin anti-thrombin complexes (TATs), and soluble 
adhesions molecules (sICAM-1 and sVCAM-1) were increased. Post treatment soluble P 
selectin (PS/PVP 26.7±7.1 vs 36.6±9.9; TAGP 28.7±7.2 vs 43.5±8.4 ng/mL, p<0.001), and 
soluble CD40 ligand (PS/PVP 297±228 vs 552±272, TAGP 245±187 vs 390±205 ng/mL, 
p<0.05) increased. Post-dialyzer concentrations increased vs pre-dialyzer for tissue factor 
(PS/PVP 117±12 vs 136±16, TAGP 100±25 vs 128±40 ng/mL, p<0.05), factor VIIIc 
(PS/PVP 174±54 vs 237±83, TAGP 163±60 vs 247±102 IU/mL, p<0.01), sVCAM-1 
(PS/PVP 782±64 vs 918±140, TAGP 722±121 vs 889±168 ng/mL, p<0.01), and D-Dimers 
(PS/PVP 292±132 vs 355±167, TAGP 300±129 vs 391±171 ng/mL, p<0.001). There was no 
macroscopic thrombus noted in the ECC, and no increase in microparticles, platelet factor-4, 
or TATs.  
Discussion 
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Despite being pro-thrombotic, with activation of platelets, and lymphocytes during passage 
through ECC, no macroscopic clotting, or increased TATs were noted during OL-HDF, and 
no major differences between cellulosic and polysulphone dialyzers. 
 
 
 
Introduction 
 Although patients with chronic kidney disease stage 5 who are manged conservatively 
without dialysis have an increased bleeding time due to a functional platelet defect [1], 
patients with both acute kidney injury and haemodialysis patients are pro-thrombotic [2,3], 
with increased risk of clotting in the extra-corporeal circuit [4]. As such, circuit clotting was a 
major limitation of the early haemodialysis circuits, and it was only overcome with the 
introduction of heparin [5]. Over time, with the technical advances in circuit and dialyzer 
design, manufacturing processes to improve internal surface smoothness of dialyzer fibres 
and blood lines, coupled with the development of bio-incompatible polymers that the risk of 
extracorporeal circuit clotting has declined to now be a relatively unusual complication of 
outpatient dialysis sessions. Indeed, the amounts of heparin now administered are much less 
than those 20 years or so ago [6]. 
 Traditionally haemodialysis treatments have centred on the clearance of urea by 
diffusion. As such capillary dialyzers, have been designed to have fibres with narrow internal 
diameters to minimise the distance required for solutes to diffuse. Over the last decade there 
has been an increased interest in adding convective clearance to standard diffusion, to 
increase middle sized solute clearances [7]. More recently studies have reported that 
increasing the amount of convective loss, termed high volume on-line haemodiafiltration is 
associated with decreased patient mortality [8,9]. However, increasing convective volume 
exchange in patients with acute kidney injury increases the risk of circuit clotting [10], as the 
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greater the filtration fraction then the greater the increase in haemoconcentration and protein 
concentrations as blood flows through the capillary dialyzer [11]. This leads to an increase in 
pressure within the dialyzer, which will either lead to activation of pressure alarms and so 
stopping convection, or potentially rupture of the dialyzer casing.  
To allow for the delivery of higher convective volume exchanges, a newer generation 
of dialyzers, designed to have wider diameter capillary fibres have been developed. However, 
this potentially allows a greater change in hydrostatic pressure to occur as blood passes 
through the dialyzer and changes in pressure and flow patterns may potentially lead to 
increased platelet and leukocyte activation and increase the risk of clotting in the 
extracorporeal circuit. To investigate whether haemodiafiltration is associated with increased 
risk of clotting we measured markers of platelet activation and activation of the clotting 
cascade during haemodiafiltration with two dialyzers of different fibre composition.  
 
Patients and methods 
10 patients attending for thrice weekly outpatient haemodialysis, who had been 
dialyzing with polyethersulphone and polyvinylpyrrolidone (PVP) dialyzers (ELISIO-21H, 
Nipro Corp., Osaka, Japan) were enrolled into the study. Patients were then switched to either 
dialysing with a polysulphone (PS) and PVP dialyzer (Fresenius FX100, Fresenius GMB, 
Bad Homburg, Germany) or an asymmetric triacetate (ATA) (SOLACEA-21H, Nipro Corp., 
Osaka, Japan) (table 1). Patients dialysed for a minimum of three dialysis sessions with each 
dialyzer before they were studied, followed by a washout period returning to dialysing with 
the ELISIO dialyzer for a minimum of one week, before starting with the other trial dialyzer. 
All patients were studied during the same weekly dialysis session.  
All 10 patients dialysed using arteriovenous fistulae. Dialysis schedules were kept 
constant in terms of dialysate composition and dialysate flow dialysis machine (BBraun, 
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Dialogue+, BBraun, Melsungen, Germany). (table 2). Constant ultrafiltration rate profiles 
were used in all cases, and patients dialysed supine in beds. Haemoglobin was measured pre- 
and post-dialysis (XE-2100 Sysmex Corporation, Kobe, Japan) [12], and serum albumin 
samples analysed by the bromocresol green method (Roche Integra, Roche diagnostics, 
Lewes, UK) and total protein by a modified biuret method [13]. 
 All patients were anticoagulated with low molecular weight heparin (tinzaparin, Leo 
Laboratories, Copenhagen, Denmark), administered into the venous limb of the circuit as a 
single bolus [14]. No patient was systemically anticoagulated with coumarins, oral anti-Xa or 
thrombin inhibitors or treated with prophylactic or treatment doses of heparin. Six patients 
were prescribed 75 mg aspirin and two prescribed 75 mg clopidogrel daily. 
 Both the dialysers and venous air detector chambers were observed during and at the 
end of the dialysis session for presence of clot formation, and assessed by a visual analogue 
scale. 
Routine Blood sampling was taken via the arterial blood line following discard of first 
10 mL at the start of dialysis and from the venous line at the end of the session. In addition, 
samples to investigate activation of clotting were also taken pre- and post-dialyzer after 15 
minutes, and pre-dialyzer after 60 minutes into 0.109 mol/L-1 sodium citrate vacutainers and 
a 4.5 mL CTAD vacutainer (sodium citrate, citric acid, theophylline, adenosine and 
dipyridamole and iloprost) (both from Becton Dickinson, Oxford, UK) to prevent platelet 
activation.  
To assess activation of the coagulation pathways we measure tissue factor (TF) and 
Factor VIIIc, and for thrombus formation and degradation we measured thrombin-
antithrombin complexes (TATs), fibrinogen and D-dimers. To determine platelet activation, 
we measured platelet factor 4 (PF4), plasma microparticles, soluble P selectin, and soluble 
CD40 ligand, which is expressed and shed by activated T cells activating platelets. To 
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estimate activation of leukocytes we measured soluble E selectin and vascular cell adhesion 
molecule 1 (sVCAM-1) as endothelial derived leukocyte adhesion and activation molecules, 
and soluble intercellular adhesion molecule 1 (sICAM-1) as a marker of monocyte activation. 
All plasma samples were prepared by double centrifugation (12 minutes each spin) at 
2000 g, separated, aliquoted and frozen at -85oC until testing. In addition to standard 
coagulation screen prothrombin time (PT) and activated partial thromboplastin time (aPTT), 
fibrinogen was measured using the Clauss method, d-Dimers (ng/mL) using HemosIL D-
Dimer kit and factor (F) VIII:C levels were measured by one stage clotting factor assay on an 
ACLTOP (all Instrumentation Laboratory (IL), Bedford, MA, USA), TAT complexes 
(Abcam, Cambridge, UK). The CTAD plasma samples were used for the measurement of 
plasma platelet activation markers PF4 by ELISA (Zymutest, Hyphen Biomed, Neuville-sur-
Oise, France) and soluble (s) sPselectin (R&D systems Bio-Techne Ltd, Abingdon, UK). 
Plasma levels of the following adhesion molecules were determined by ELISA: soluble (s) 
CD40 ligand (R&D Systems), sICAM-1, sVCAM-1 (R&D Systems). Tissue factor was 
measured using the Actichrome TF assay (R&D Systems). Plasma microparticles were 
measured using the Zymuphen MP-Activity assay (Hyphen Biomed) in platelet poor plasma 
(PPP) [2,15]. 
 
Ethical approval was granted by London-Westminster Ethics Committee (15/LO/0102) 
and the trial registered NCT02546037. All patients provided informed written consent in 
keeping with the principles of the declaration of Helsinki. 
 
Statistics 
Results are expressed as mean ± standard deviation, or median and interquartile range, 
or percentage. Statistical analysis was by students’ paired t test for parametric data and by the 
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Wilcoxon rank sum pair test for nonparametric data, and by ANOVA or Kuskal Wallis, with 
appropriate ad hoc correction for multiple testing (Graph Pad Prism version 6.0, Graph Pad, 
San Diego, CA, USA, and SPSS version 24.0, Univ Chicago, Illinois, USA). Statistical 
significance was taken at or below the 5% level. 
 
 
 
Results 
We studied 10 patients, 70% male, mean age 74.5±8.8 years, with a median dialysis 
vintage of 42.9 months (27.1-63.5). The underlying renal diseases included secondary to 
diabetes in 3, reno-vascular disease in 2, one case each for myeloma (stable paraprotein < 1 
g/L), membranous glomerulonephritis, polycystic kidney disease, and 2 cases of 
undetermined aetiology. There were no differences in dialysis session times, blood flows or 
convection volumes (table 2). Although the urea clearances obtained with the PS and PVP 
dialyzer were marginally greater than those for the ATA dialyzer, these differences were not 
significant. However, post-haemodiafiltration β2 microglobulin was lower with the PS and 
PVP dialyzer; 5.7±1.2 vs 8.0±2.2 mg/L after correction for the change in haematocrit, with a 
81.3±4.5 vs 73.8±6.0 % reduction in serum concentrations, p<0.05 (table 3). 
 Apart from the increase in haematocrit due to net ultrafiltration, there were no 
significant changes in peripheral white blood cell or platelet counts comparing pre- and post-
haemodiafiltration samples. Visual inspection of the dialyzers at the end of the treatment 
session did not show any significant clotting in the dialyzer headers. Similarly, there was 
none or < 10% clotting in the venous air-detector chamber. The mean PT remained within 
normal limits (< 14 seconds) during treatment with both dialyzers. The aPTT was normal at 
the start of haemodiafiltration, then increased due to the effect of heparin, and returned to 
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normal at the end of the session. APTT results were not different pre- vs post-dialyzer after 
15 minutes, suggesting no significant heparin loss during passage through the dialyzer. 
 Thrombin-antithrombin complexes (TATs) did not increase during haemodiafiltration 
treatments (table 4). However, 15 minutes into the dialysis session factor VIII:C, Clauss 
fibrinogen, tissue factor (TF) and D-dimers were all greater post-dialyzer compared to pre-
dialyzer sampling. In addition, both sICAM-1 and sVCAM-1 were also greater post- vs pre-
dialyzer after 15 minutes, as was sEselectin. Whereas microparticles and platelet factor 4 
(PF4) did not increase with haemodiafiltration, both sPselectin and soluble CD40 ligand 
(sCD40L) were greater at the end of the haemodiafiltration session compared to the start.  
Factor VIIIc was also higher at the end of the session with the PS and PVP dialyzer (p=0.034, 
adjusted for multiple testing). 
 As the coagulation results were similar for the two dialyzers, we combined data and 
compared the effects of taking anti-platelet agents (aspirin and clopidogrel). We found no 
demonstrable differences between dialysis sessions in those prescribed and not prescribed 
anti-platelet agents (supplementary table). 
 
Discussion 
 The introduction of cellulosic dialyzers was a major advance in the history of 
haemodialysis [5]. However, it was soon realised that these dialyzers activated complement, 
platelets, and leukocytes. This led to the development of modified cellulosic dialyzers, 
reducing net negative charge, with the introduction of cellulose diacetate and triacetate (CTA) 
membranes, and the manufacture of synthetic membranes designed to improve 
haemocompatibility [16]. These newer dialyzer membranes, and changes in dialyzer 
sterilisation processes, reduced reactions to haemodialysis [17], and as such further 
developments in dialyzer design were aimed at increasing small solute urea clearances [18]. 
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However clinical trials designed to investigate the effect of greater urea clearance did not 
show any benefit in terms of patient survival, and despite the technical advances in dialysis 
technology 5-year patient survival remained lower than that for some of the more common 
solid organ cancers [19]. Attention then turned to increasing clearance of larger sized 
azotaemic retention products of metabolism by introducing haemodiafiltration [7]. Once 
again, the initial studies did not show any survival advantage, but more recently trials of high 
volume on-line haemodiafiltration [9], in terms of absolute volumes, and also when adjusted 
for body size [8] showed improved patient survival compared to low flux and high flux 
haemodialysis. However, to achieve these higher convective clearance targets dialyzers need 
to be modified to achieve higher hydraulic permeability, without excessive 
haemoconcentration. Proteins are deposited on the dialyzer membrane during dialysis, 
including the serine proteases factor XII, factor X1, and fibrinogen. As such high volume 
haemodialfiltration could potentially increase clotting within the dialyzer capillary fibres, and 
so reduce volume exchanges. 
 To investigate the effects of haemodialfiltration on clotting in the extracorporeal 
circuit we chose to study two dialyzers designed for to increase convective clearances, one 
with a modified asymmetric triacetate membrane (ATA) and one synthetic membrane (PS 
and PVP). We did not observe any significant clotting in the extracorporeal circuit, in terms 
of external examination of the dialyzer header and venous air detector, and standard pressure 
measurements of the extracorporeal circuit were not different between the dialyzers. There 
was no difference in small solute, urea clearances when using the two dialyzers, and no 
difference in convective exchange. Although there were no differences in the absolute pre- 
and post-haemodiafiltration β2 microglobulin concentrations, the relative reduction was 
greater with the PS and PVP dialyzers. This small difference may potentially be due to the 
higher sieving coefficient and larger membrane surface area, although as we only made blood 
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side measurements cannot exclude any membrane adsorption [20]. All patients were 
anticoagulated with a single heparin bolus, administered into the venous limb of the circuit at 
the start of treatment [14]. There was no change in prothrombin times, the aPTT increased, 
but there was no difference in samples taken pre- and post-dialyzer, suggesting no significant 
loss during dialyzer passage. To test for activation of the indirect clotting pathway we 
measured factor VIIIc and tissue factor for direct clotting pathway activation. Previous 
reports have demonstrated increased factor VIII with older generation cellulosic membranes 
[21]. However, we found that factor VIIIc concentrations initially fell with both dialyzers, but 
were increased on passage through the dialyzer. Thereafter they were stable, but factor VIIIc 
was greater at the end of the session with the PS and PVP dialyzer. Tissue factor 
concentrations were increased at the start of treatment, and the post-dialyzer concentrations 
were increased compared to in-let concentrations, but thereafter did not increase with 
treatment. Other studies have demonstrated that adhesion of cells, including leukocytes to the 
dialyzer membrane surface, leads to the release of tissue factor [22]. Fibrinogen 
concentrations similarly increased post-dialyzer compared to in-let, but did not change over 
time. To study whether these changes in clotting cascade proteins lead to clot formation we 
measured D-Dimers and TATs. We found that D-Dimers increased in the dialyzer outlet 
samples with both dialyzers, in keeping with previous reports using PS dialyzers [23], but 
there was no significant increase in TATs post-dialyzer or increase with treatment duration. 
These results demonstrate that clot formation was minimal, as earlier studies have reported 
increased TATs within minutes of starting haemodialysis [24]. 
 More recently the role of activation of the contact coagulation pathway in initiating 
clotting in the extracorporeal circuit has been questioned [25], with increased attention to 
platelet activation [26], and the generation of microparticles [27]. Whereas previous studies 
have reported increased microparticle generation [28], we found that with these dialyzers 
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designed for high volume haemodiafiltration there were no significant increases in 
microparticles. Similarly, PF4 was not increased post-treatment.  However, we did observe an 
increase in the post-dialyzer sVCAM-1, sICAM-1, and sEselectin compared to the in-let 
samples, and post-treatment sCD40L and sPselectin concentrations were increased. Although 
sEselectin and sVCAM-1 are released from activated endothelial cells, previous reports from 
dialyzer studies have reported release of endothelial factors during dialysis [21]. sVCAM-1 
concentrations at the end of the dialysis sessions were higher with the PS and PVP dialyzer. 
These soluble adhesion molecules activate lymphocytes and platelets, and both sCD40L 
which is released from activated T lymphocytes, and sPselectin which is released from 
activated platelets, increased at the end of dialysis session with both dialyzers.  As such our 
findings are in agreement with previous studies [29]. 
 The majority of our patients were prescribed aspirin or clopidogrel at a standard dose 
of 75 mg. We did not find any difference in coagulation cascade activation, or activation 
markers of platelets, leukocytes or monocytes in those prescribed anti-platelet agents. 
However, patients were prescribed a standard dose without any formal platelet mapping 
studies, and as such it is unclear as to how many of our patients received an effective 
therapeutic dose.   
 Although we have demonstrated increased platelet and leukocyte activation during 
passage through the dialyzer, with increased production of tissue factor and D dimers with 
both dialyzers.  We performed post-dilution haemodialfiltration, and previous studies have 
suggested that pre-dilution may cause less clotting in extracorporeal circuits, although 
potential increased loss of low molecular weight heparins may limit any advantage [30]. Even 
so, we did not note any macroscopic evidence of clotting in the extra-corporeal clotting. More 
recently there have been reports suggesting that achieving higher convective exchanges is 
associated with greater patient survival [31,32], although in part this may relate to more 
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reliable vascular access and patient factors [33]. The convective volume exchanged achieved 
in our study was similar to the average reported from the recent trials of haemodiafiltration 
[32], but was not specifically targeted to what would now be considered to be high volume 
exchange. As such high volume exchange with greater intra-dialyzer pressures could lead to 
greater activation of platelets, leukocytes with increased potential for clotting.   
Earlier studies reported that dialyzer membranes can activate complement; PS 
dialyzers by both the alternative and lectin pathways, whereas cellulosic dialyzers activate the 
classic pathway [34]. As complement activation can increase microparticle production and 
clotting [27], then, this could potentially have led to differences between the two different 
dialyzers. However, more recent studies using modern day dialyzers reported minimal 
complement activation [28], and we did not find any clinically significant differences 
between the two dialyzers, in terms of small solute clearances or changes in β2-microglobulin 
concentrations. One previous study has suggested less platelet activation with 
haemodialfiltration compared to standard haemodialysis [35], and our study would suggest 
that dialyzer membranes, made from asymmetric triacetate (ATA) and PS and PVP, designed 
for high volume on-line haemodiafiltration, allow the achievement of high volume exchanges 
without an increased risk of extracorporeal circuit clotting. 
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Table 1. Dialyzer membrane characteristics 
 
Dialyzer FX-100 SOLACEA-21H 
Fibre composition polysulphone/polyvinylpyrrolidone 
(PS/PVP) 
asymmetric 
triacetate(ATA) 
sterilisation in-line steam dry gamma irradiation 
effective surface area  2.2 m2 2.1 m2 
Wall thickness  35 µm 25 µm 
Internal diameter 185 µm 200 µm 
Effective length  254 mm 
Priming volume  116 mL 118 mL 
Ultrafiltration coefficient  73 mL/h.mmHg 76 mL/h.mmHg 
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Table 2. Dialysis session variables when using FX100 and SOLACEA-21H dialyzers.  
Results expressed as mean ±SD, or median (interquartile range). There were no statistical 
differences between treatments using the two different dialysers. 
 
Variable FX-100 SOLACEA-21H 
Session time hours 3.65 ±0.34 3.65 ±0.34 
Blood flow mL/min 320 (320-350) 320 (320-350) 
Arterial pressure mmHg -100 (-89.5 to - 123) -106 (-89.8 to - 130) 
Venous pressure mmHg 170 (156 - 182) 150 (144 - 170) 
Transmembrane pressure mmHg 266 (251-289) 264 (238-316) 
Needle gauge 15 (15.0 – 15.3) 15 (15.0 – 15.3) 
Heparin dose IU 2000 (1250-2750) 2000 (1250-2750) 
Convection volume L/session 18.0 ±1.8 17.8 ±1.9 
Substitution rate mL/kg/min 1.15 ±0.23 1.11 ±0.24 
Dialysate flow mL/min 500 (500-525) 500 (500-525) 
On-line Kt/Vurea 1.77 ±0.36 1.53 ±0.18 
Single pool Kt/Vurea 1.80 ±0.31 1.72 ±0.40 
Urea reduction ratio % 78.5 ±5.8 76.6 ±7.6 
Dialysate temperature °C 35.0 (35.0 – 35.1) 35.0 (35.0 – 35.1) 
Dialysate sodium mmol/L 137.0 ±1.34 137 ±1.34 
Dialysate potassium mmol/L 2.0 (1.0-2.0) 2.0 (1.0-2.0) 
Dialysate calcium mmol/L 1.25 ±0.17 1.25 ±0.17 
Dialysate magnesium mmol/L 0.5 0.5 
Dialysate bicarbonate mmol/L 32.0 32.0 
Dialysate acetate mmol/L 3.0 3.0 
Dialysate glucose mmol/L 5.5 5.5 
 
  
20 
 
Table 3. Changes in pre- and post weights, blood pressure (systolic – SBP, diastolic – DBP) 
and serum biochemistry and full blood counts (total white blood cell (WBC), 
polymorphonuclear leukocyte (PMN), peripheral blood lymphocytes (PBL using FX100 and 
SOLACEA-21H dialyzers. Results expressed as mean ±SD, or median (interquartile range). 
There were no statistical differences pre-dialysis. * p<0.05 post-dialysis FX-100 vs 
SOLACEA-21H. 
 
 
 FX-100 FX-100 SOLACEA-
21H 
SOLACEA-
21H 
 Pre-dialysis Post-dialysis Pre-dialysis Post-dialysis 
Weight kg 69.4 ±11.4 69.3 ±11.5  69.7 ±10.9 67.7±11.2 
Weight loss kg  1.58±0.84  1.67±0.69 
SBP mmHg 143 ±18.7 132 ±26.6 144 ±15.4 127 ±17.2 
DBP mmHg 71.2 ±13.7 68.4 ±13.1 71.4 ±13.5 68.5 ±8.7 
Sodium 
mmol/L 
139 ±4.3 140 ±1.4 139 ±2.9 140 ±0.8 
Potassium 
mmol/L 
5.49 ±0.81 3.59 ±0.34 5.66 ±0.84 3.72 ±0.54 
Urea mmol/L 20.9 ±7.5 4.5 ±2.0 20.9 ±7.2 5.1 ±2.9 
Creatinine 
µmol/L 
637 (577-
837) 
177 (147-
278) 
658 (605-852) 194 (147-
289) 
Albumin g/L 39.2 ±2.6 41.4 ±3.9 39.3 ±1.8 41.7 ±2.8 
Total protein 
g/L 
67.3 ±5.0 73.2 ±7.0 68.0 ±4.9 72.6 ±5.4 
β2 
microglobulin 
mg/L 
31.7 ±8.3 6.0 ±1.4* 31.2 ±8.3 8.3 ±2.3 
Haemoglobin 
g/L 
111 ±9.0 122 ±14.4 111 ±11.3 119 ±13.4 
Haematocrit  0.35 ±0.01 0.37 ±0.03 0.35 ±0.01 0.36 ±0.03 
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WBC 109/L 6.03 ±1.30 5.66 ±1.42 6.06 ±1.63 6.17 ±2.13 
Platelets 109/L 211 (187-
240) 
220 (197-
272) 
219 (191-238) 216 (197-
251) 
PMN 109/L 3.92 ±1.18 3.76 ±1.13 4.0 ±1.48 4.10 ±1.81 
PBL 109/L 1.26 ±0.36 1.19 ±0.04 1.23 ±0.41 1.32 ±0.51 
Monocytes 
109/L 
0.61 ±0.19 0.47 ±0.13 0.53 ±0.16 0.46 ±0.18 
Eosinophils 
109/L 
0.23 ±0.09 0.22 ±0.09 0.28 ±0.13 0.28 ±0.13 
Basophils 
109/L 
0.02 ±0.01 0.02 ±0.02 0.02 ±0.01 0.02 ±0.01 
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Table 4. Changes in clotting studies during haemodiafiltration using FX-100 and SOLACEA-
21H dialyzers.  PT seconds (s), APTT (s), thrombin-anti-thrombin complexes (TATs), 
soluble Intercellular adhesion  molecule 1 (sICAM-1), soluble vascular cell adhesion 
molecule 1 (sVCAM-1), soluble CD40 ligand (sCD40L), microparticle activity (MP), platelet 
factor 4 (PF4). Normal reference ranges given in parentheses. * p<0.05, ** p<0.01, *** 
p<0.001 vs Start, # p<0.05, ## p<0.01, ###p<0.001 15 minute pre- vs post- dialyser. 
 
 Start Pre-dialyzer  
15 min 
Post-
dialyzer  
15 min 
60 min End 
PT s (<14 s)     
FX-100 11.3±0.8 12.3±0.8 12.1±0.8 11.9±0.9 11.1±0.8 
SOLACEA-
21H 
11.2±0.8 12.3±0.8 11.9±0.8 11.6±0.7 11.2±0.7 
aPTT s (<45 s)     
FX-100 31.9±2.5 66.9±23*** 77.4±33.8* 47.3±16.2 33.4±4.3 
SOLACEA-
21H 
32.1±1.7 68.7±23.9** 82.0±30.5* 50.0±16.9* 35.2±11.2 
Fibrinogen g/L (1-3)     
FX-100 3.92±0.99 3.65±0.82### 4.87±1.39* 4.15±1.79 4.19±1.2 
SOLACEA-
21H 
3.83±1.18 3.63±1.21### 5.73±1.6* 3.91±1.35 3.95±1.65 
Factor VIIIc 
IU/mL 
(< 200)     
FX-100 202±62 174±54***## 237±83 195±61 224±77* 
SOLACEA-
21H 
191±72 163±60*## 247±102** 183±68 207±86 
Tissue Factor 
pg/mL 
(21-49)     
FX-100 124±16 117±12## 136±15** 123±11 120±15 
SOLACEA- 103±24 100±25# 128±40* 103±22 103±27 
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21H 
D dimers ng/mL (<250)     
FX-100 301±146 292±132## 355±167** 315±167 386±240 
SOLACEA-
21H 
314±136 300±129## 391±171* 307±126 502±492 
TATs ng/mL (0.5-1.0)     
FX-100 9.2±3.8 10.2±5.9 10.7±5.0 9.4±4.7 8.6±4.7 
SOLACEA-
21H 
9.1±6.7 10.5±6.3 10.9±5.2 10.3±5.9 9.1±5.5 
sICAM-1 
ng/mL 
(71-185)     
FX-100 199±110 194±106## 225±92* 208±96 213±106 
SOLACEA-
21H 
192±88 197±90# 250±105* 205±87 220±124 
sVCAM-1 
ng/mL 
(395-594)     
FX-100 780±69 782±64### 918±140** 804±103 829±100 
SOLACEA-
21H 
733±119 722±121## 889±168* 747±134 729±80 
sE-selectin 
ng/mL 
(13-51)     
FX-100 37.6±11.8 36.4±11.8# 42.9±14.3 36.9±12.1 40.1±14.7 
SOLACEA-
21H 
37.3±11.3 37.9±12.7# 47.9±10.4* 38.7±11.7 38.3±11.4 
sCD40L ng/mL      
FX 100  297±228 503±247 352±264 600±411 552±272* 
SOLACEA-
21H 
245±187 336±193 381±220** 372±195 390±205* 
MP nM/mL      
FX 100 6.2±1.8 8.1±3.6 5.1±2.4 8.8±4.8 10.2±8.1 
SOLACEA-
21H 
11.0±9.0 10.8±10.4 7.4±5.0 12.1±7.4 11.3±6.8 
sPselectin (< 60)     
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ng/mL 
FX 100 26.7±7.1    37.6±9.9*** 
SOLACEA-
21H 
28.7±7.2    43.5±8.4*** 
PF4 ng/mL (<10)     
FX 100 58.3±9.9    55.1±3.3 
SOLACEA-
21H 
52.7±6.5    57.4±2.2 
 
 
